Merck announced FDA granted breakthrough therapy designation for V116, investigational 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults
|

Merck announced FDA granted breakthrough therapy designation for V116, investigational 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults

On Apr. 14, 2022, Merck announced that V116, the companyï¾’s investigational 21-valent pneumococcal conjugate vaccine, had received Breakthrough…

Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
| | | | |

Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19

On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…

Icosavax announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).

Icosavax announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).

On Mar. 25, 2022, Icosavax announced the first subjects had been dosed with IVX-411, a virus-like particle (VLP)…